Overview Financials News + Filings Key Docs Ownership
All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Quarterly results
|
|
Legend Biotech Corp (LEGN)
|
Create: Alert |
All | News | Filings
| Date Filed | Type | Description |
| 08/15/2023 |
6-K
| Quarterly results |
| 05/18/2023 |
6-K
| Quarterly results |
| 06/01/2022 |
6-K
| Quarterly results |
| 03/18/2022 |
6-K
| Quarterly results |
| 11/16/2021 |
6-K
| Quarterly results |
| 08/23/2021 |
6-K
| Quarterly results |
| 05/18/2021 |
6-K
| Quarterly results |
| 03/18/2021 |
6-K
| Quarterly results |
| 11/16/2020 |
6-K
| Quarterly results|
Docs:
|
"6-K",
"Legend Biotech Reports Third Quarter 2020 Financial Results SOMERSET, N.J.—— November 16, 2020—Legend Biotech Corporation , a global clinical-stage biopharmaceutical company engaged in the discovery and development of novel cell therapies for oncology and other indications, today reported financial results for the quarter ended September 30, 2020. “Legend Biotech continues to execute on our corporate strategy, advancing the development of our lead product candidate, ciltacabtagene autoleucel , in collaboration with Janssen Biotech, Inc. as well as our other pipeline programs,” said Dr. Ying Huang, Chief Executive Officer and Chief Financial Officer of Legend Biotech. “We look forward to initiation of the Biologics License Application filing for cilta-cel by Janssen Biotech, Inc.” Third Qua..." |
|
| 08/31/2020 |
6-K
| Quarterly results |
|
|